Investigating how a specific immune response affects side effects of cancer immunotherapy
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
This study is looking at how a part of the immune system called the NLRP3 inflammasome might cause side effects in cancer patients receiving a specific type of treatment, and it aims to find ways to better manage these side effects, especially in the lungs and colon.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11309702 on NIH RePORTER |
What this research studies
This research explores the role of the NLRP3 inflammasome in the immune-related adverse events (irAEs) that can occur with anti-PD-1 antibody immunotherapy in cancer treatment. By using a genetically engineered model of melanoma, the study aims to understand how these adverse events develop and how they can be managed more effectively. The researchers are particularly focused on the mechanisms that lead to inflammation in the lungs and colon, which are common sites of toxicity. The findings could help improve treatment protocols and reduce the negative impacts of immunotherapy on patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing anti-PD-1 antibody immunotherapy for cancer treatment.
Not a fit: Patients who are not receiving immunotherapy or those with conditions unrelated to cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management of side effects associated with cancer immunotherapy, improving patient quality of life.
How similar studies have performed: Other research has shown promise in understanding immune-related adverse events in cancer therapies, but this specific approach is novel.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Hanks, Brent Allen — Univ of North Carolina Chapel Hill
- Study coordinator: Hanks, Brent Allen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.